Literature DB >> 3481362

Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma.

S Martino1, D A Decker, H E Hynes, C L Kresge.   

Abstract

Sixteen women with advanced epithelial ovarian carcinoma were treated with Aclacinomycin-A 40 mg/M2 given as a weekly infusion for four consecutive weeks followed by a two week rest period. All had failed prior chemotherapy. No responses were observed. Nausea and vomiting were the most frequent side effect. Myelosuppression was minimal. This dose and schedule of Aclacinomycin-A are not recommended for further trials in ovarian carcinoma.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3481362     DOI： 10.1007/BF00169977

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

1.  New antitumor antibiotics aclacinomycins A and B.

Authors:  T Oki; Y Matsuzawa; A Yoshimoto; K Numata; I Kitamura
Journal:  J Antibiot (Tokyo)       Date:  1975-10       Impact factor: 2.649

2.  Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity.

Authors:  S Hori; M Shirai; S Hirano; T Oki; T Inui; S Tsukagoshi; M Ishizuka; T Takeuchi; H Umezawa
Journal:  Gan       Date:  1977-10

3.  Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.

Authors:  C Karanes; J D Young; M K Samson; L B Smith; L A Franco; L H Baker
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Experimental and clinical studies on aclarubicin in the treatment of solid tumors.

Authors:  K Kumai; T Kubota; K Ishibiki; O Abe
Journal:  Biomed Pharmacother       Date:  1984       Impact factor: 6.529

5.  Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.

Authors:  B A Levey; E Ruiz; B Rogerson; D C Lehotay; G S Levey
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.